CBA Florida Inc. (fka CBAI)

[MrLong]

Viacell Sterile Bags - Looks like Perkin Elmer has permitted CBAI use of some pretty special technology.

Two manufacturing processes
Family-related no IND BLA needed not a drug unless manipulated
OBGYN PE screening--> CB & PLAC PE Viacell pat/Celgene pat storage ---> release ----> transplant

Unrelated or manipulated Pharma Drug
OBGYN PE screening--> CB & PLAC PE Viacell pat/Celgene pat storage ---> Registry release ----> transplant(drug)

Pharma manufacturing biologics
Genzyme
Osiris
Celgene

CBAI is a bank permitted use of PE technlogy today as are a few others. Pharma needs inventory and maybe these few privates using PE sterile bags are consolidating.


Marc Beer — ViaCell, Inc.—President and CEO

We have been successful in the last 12 months of launching a couple differentiators that have caused a market share gain and momentum for us as an organization. One is the only FDA-approved collection bag. It went to a full FDA approval and it is the only fully FDA-approved sterile collection bag on the market. We also have an FDA-approved automation technology for processing the cells in our high-throughput lab. So we have worked hard as an organization of tying best-in-science quality and regulatory hurdles to differentiating ourselves in the market. And I think in the eyes of the consumer and the OB, we do offer a differentiated product offering, and it shows in our growth.

PE when it entered a definitive merger with Viacell est revs for genetic screenings of expectant mothers to be approx $500m in 2010. If they capture the entire 4.2m mkt then it's low... very modest est.

We have the sterile bag today. Breer is the Genzyme CEO today and Viacell/Viacord has tech agreements with Genzyme. Genzyme has funded Osiris. PE has extended the bag technology to CBAI and Celgene permits use of placenta patent.